Bill Gates, Other Donors Commit $30M To Venture Fund Aimed At Developing Alzheimer’s Diagnostic Test

CNN: Bill Gates jump-starts research for an affordable Alzheimer’s test
“…Gates announced [Tuesday] that he has joined a coalition of philanthropists who are investing $30 million to create a venture fund called Diagnostics Accelerator. ‘We need a better way of diagnosing Alzheimer’s — like a simple blood test or eye exam — before we’re able to slow the progression of the disease,’ Gates wrote in a statement announcing the investment…” (LaMotte, 7/17).

Financial Times: Bill Gates to back new Alzheimer’s research fund
“…[T]he biggest problem is that Alzheimer’s is almost always diagnosed after a patient has started exhibiting memory loss, at which point the disease has already inflicted significant damage to the brain. A majority of Alzheimer’s researchers think this delay is partly responsible for the failure to find a drug that can halt or reverse the disease…” (Crow, 7/17).

TIME: It’s Nearly Impossible to Diagnose Alzheimer’s Disease in Living People. Bill Gates Wants to Change That
“…[T]he Diagnostics Accelerator, a project with the Alzheimer’s Drug Discovery Foundation (ADDF), … will focus on creating new strategies for diagnosing the disease. Gates is joined by Leonard Lauder, co-founder of the Alzheimer’s Drug Discovery Foundation, the Dolby Family, and the Charles and Helen Schwab Foundation, among others in the effort…” (Park, 7/17).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.